{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:39:27Z","timestamp":1792737567073,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.medj.2024.09.004","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T10:31:39Z","timestamp":1728556299000},"page":"100515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Humoral signatures of Caspr2-antibody spectrum disorder track with clinical phenotypes and outcomes"],"prefix":"10.1016","volume":"6","author":[{"given":"Paula","family":"Terroba-Navajas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Spatola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Chuquisana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juna M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Dik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marmolejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordan","family":"Lauc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stjepana","family":"Kovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Pr\u00fcss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Titulaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan D.","family":"L\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.09.004_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrneurol.2017.43","article-title":"The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis","volume":"13","author":"van Sonderen","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.medj.2024.09.004_bib2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/glia.22968","article-title":"Assembly of juxtaparanodes in myelinating DRG culture: Differential clustering of the Kv1\/Caspr2 complex and scaffolding protein 4.1B","volume":"64","author":"Hivert","year":"2016","journal-title":"Glia"},{"key":"10.1016\/j.medj.2024.09.004_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.1097","article-title":"Potassium channel antibodies in two patients with reversible limbic encephalitis","volume":"50","author":"Buckley","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.medj.2024.09.004_bib4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1212\/WNL.54.3.771","article-title":"Morvan's syndrome associated with voltage-gated K+ channel antibodies","volume":"54","author":"Barber","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.09.004_bib5","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.medj.2024.09.004_bib6","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","article-title":"Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series","volume":"9","author":"Lai","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2024.09.004_bib7","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/ejn.14081","article-title":"Contactin-associated protein-like 2, a protein of the neurexin family involved in several human diseases","volume":"48","author":"Saint-Martin","year":"2018","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.medj.2024.09.004_bib8","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/jnnp-2020-323226","article-title":"Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features","volume":"91","author":"Mu\u00f1iz-Castrillo","year":"2020","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.medj.2024.09.004_bib9","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1212\/NXI.0000000000000127","article-title":"Caspr2 autoantibodies target multiple epitopes","volume":"2","author":"Olsen","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2024.09.004_bib10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","article-title":"The clinical spectrum of Caspr2 antibody\u2013associated disease","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.09.004_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ana.25120","article-title":"Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia","volume":"83","author":"Patterson","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.medj.2024.09.004_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ana.26345","article-title":"Human CASPR2 Antibodies Reversibly Alter Memory and the CASPR2 Protein Complex","volume":"91","author":"Joubert","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.medj.2024.09.004_bib13","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1093\/brain\/awz119","article-title":"Behaviour and neuropathology in mice injected with human contactin-associated protein 2 antibodies","volume":"142","author":"Giannoccaro","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.medj.2024.09.004_bib14","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/brain\/aww062","article-title":"Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects","volume":"139","author":"Manso","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.medj.2024.09.004_bib15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.neuron.2018.01.033","article-title":"Immune or Genetic-Mediated Disruption of CASPR2 Causes Pain Hypersensitivity Due to Enhanced Primary Afferent Excitability","volume":"97","author":"Dawes","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.medj.2024.09.004_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00401-017-1751-5","article-title":"Persistent microglial activation and synaptic loss with behavioral abnormalities in mouse offspring exposed to CASPR2-antibodies in utero","volume":"134","author":"Coutinho","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.medj.2024.09.004_bib17","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000075","article-title":"Complement-associated neuronal loss in a patient with CASPR2 antibody\u2013associated encephalitis","volume":"2","author":"K\u00f6rtvelyessy","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2024.09.004_bib18","first-page":"1137","article-title":"Systematic review of the clinical spectrum of CASPR2 antibody syndrome","volume":"267","author":"Boyko","year":"2020","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.medj.2024.09.004_bib19","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1172\/JCI130029","article-title":"Functional diversification of IgGs through Fc glycosylation","volume":"129","author":"Wang","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2024.09.004_bib20","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2024.09.004_bib21","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2024.09.004_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00401-022-02448-x","article-title":"Complement activation contributes to GAD antibody-associated encephalitis","volume":"144","author":"Chuquisana","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.medj.2024.09.004_bib23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/eji.202149766","article-title":"Specificity of mouse and human Fcgamma receptors and their polymorphic variants for IgG subclasses of different species","volume":"52","author":"Wang","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.medj.2024.09.004_bib24","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.173.4.1025","article-title":"The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain","volume":"173","author":"Tao","year":"1991","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.medj.2024.09.004_bib25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2024.09.004_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-cellbio-100814-125330","article-title":"Signaling and Polarized Communication Across the T Cell Immunological Synapse","volume":"32","author":"Dustin","year":"2016","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.medj.2024.09.004_bib27","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/brain\/awy109","article-title":"Distinct HLA associations of LGI1 and CASPR2-antibody diseases","volume":"141","author":"Binks","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.medj.2024.09.004_bib28","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.medj.2024.09.004_bib29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nm0395-237","article-title":"Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein","volume":"1","author":"Malhotra","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.09.004_bib30","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1073\/pnas.0702936104","article-title":"Agalactosylated IgG antibodies depend on cellular Fc receptors for in\u00a0vivo activity","volume":"104","author":"Nimmerjahn","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2024.09.004_bib31","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1172\/JCI82695","article-title":"Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity","volume":"125","author":"Quast","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2024.09.004_bib32","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1073\/pnas.91.13.6123","article-title":"Agalactosyl glycoforms of IgG autoantibodies are pathogenic","volume":"91","author":"Rademacher","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2024.09.004_bib33","doi-asserted-by":"crossref","first-page":"9868","DOI":"10.1073\/pnas.1307864110","article-title":"General mechanism for modulating immunoglobulin effector function","volume":"110","author":"Sondermann","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2024.09.004_bib34","article-title":"Humoral signatures of MOG-antibody-associated disease track with age and disease activity","volume":"4","author":"Spatola","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.medj.2024.09.004_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250228","article-title":"Emerging imaging and liquid biomarkers in multiple sclerosis","volume":"53","author":"Gill","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.medj.2024.09.004_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104456","article-title":"A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases","volume":"89","author":"Bernhardt","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.medj.2024.09.004_bib37","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V97.6.1817","article-title":"Interleukin-6 is a growth factor for nonmalignant human plasmablasts","volume":"97","author":"Jego","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.medj.2024.09.004_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic T(H)17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2024.09.004_bib39","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001076","article-title":"New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2024.09.004_bib40","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.4049\/jimmunol.1002188","article-title":"Contribution of astrocyte-derived IL-15 to CD8 T\u00a0cell effector functions in multiple sclerosis","volume":"185","author":"Saikali","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2024.09.004_bib41","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.4049\/jimmunol.1100885","article-title":"B cell-derived IL-15 enhances CD8 T\u00a0cell cytotoxicity and is increased in multiple sclerosis patients","volume":"187","author":"Schneider","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2024.09.004_bib42","doi-asserted-by":"crossref","first-page":"e931","DOI":"10.1212\/NXI.0000000000000931","article-title":"Interleukin-15 enhances proinflammatory T-cell responses in patients with MS and EAE","volume":"8","author":"Laurent","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2024.09.004_bib43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jneuroim.2008.01.016","article-title":"Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS","volume":"195","author":"Vaknin-Dembinsky","year":"2008","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.medj.2024.09.004_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2024.09.004_bib45","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.4049\/jimmunol.0900007","article-title":"A dual action of rheumatoid arthritis synovial fibroblast IL-15 expression on the equilibrium between CD4+CD25+ regulatory T\u00a0cells and CD4+CD25- responder T\u00a0cells","volume":"183","author":"Benito-Miguel","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.medj.2024.09.004_bib46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1742-2094-9-160","article-title":"Cytotoxic CD8+ T\u00a0cells and CD138+ plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies","volume":"9","author":"Melzer","year":"2012","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.medj.2024.09.004_bib47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5152\/npa.2016.15932","article-title":"Brain Infiltration of Immune Cells in CASPR2-Antibody Associated Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis","volume":"53","author":"\u00dcnverengil","year":"2016","journal-title":"Noro Psikiyatr. Ars."},{"key":"10.1016\/j.medj.2024.09.004_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.07.002","article-title":"A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation","volume":"473","author":"Fischinger","year":"2019","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.medj.2024.09.004_bib49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"Ackerman","year":"2011","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.medj.2024.09.004_bib50","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1074\/mcp.M113.037465","article-title":"Comparative performance of four methods for high-throughput glycosylation analysis of immunoglobulin G in genetic and epidemiological research","volume":"13","author":"Huffman","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.medj.2024.09.004_bib51","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3390\/biom13060954","article-title":"Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn's Disease","volume":"13","author":"Hanic","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.medj.2024.09.004_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/cpps.95","article-title":"N-Glycan Analysis by Ultra-Performance Liquid Chromatography and Capillary Gel Electrophoresis with Fluorescent Labeling","volume":"97","author":"Hanic","year":"2019","journal-title":"Curr Protoc Protein Sci"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T18:48:24Z","timestamp":1739558904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024003714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2666634024003714"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.09.004","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral signatures of Caspr2-antibody spectrum disorder track with clinical phenotypes and outcomes","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100515"}}